BACK TO PROJECTS

NHS Testbed Early Intervention Program

What is the program?

Verily has concluded its collaboration with the NHS' Heywood, Middleton and Rochdale Clinical Commissioning Group (“HMR CCG”) and Merck Sharp & Dohme Limited (“MSD”) on a NHS England Test Bed project aimed at improving care for people with long term conditions. Using data analytics and predictive modelling, the goal of the program was to identify earlier patients who either have, or are at risk of developing, chronic conditions such as heart failure, type 2 diabetes, and COPD, and to help healthcare providers better manage these conditions and reduce unplanned hospitalization. More information about the project can be found here.

How are you making it happen?

This program is part of a wider NHS ‘test bed’ initiative to study the real world impact of new technologies on service delivery and patient care. Currently, there are 15 million people in England living with long term conditions such as COPD, type 2 diabetes, and heart failure, and early identification can significantly improve patient outcomes and reduce the long term financial burden associated with these diseases. By combining MSD’s suite of healthcare tools and Verily’s risk-prediction algorithms within the NHS Heywood, Middleton and Rochdale Clinical Commissioning Group system, the team generated predictive disease models for chronic conditions in order to help health care providers identify at-risk patients earlier, and to offer more personalized interventions.

In this program, Verily used advanced analytics to develop insights from pseudonymised (or non-identifiable patient) data that the NHS leveraged to identify cohorts of patients for screening and interventional services. The goal of this program was to help practices identify potentially vulnerable patients earlier, so that they could intervene sooner. As a test bed for innovation, this program aimed to both improve patient outcomes within the wider Greater Manchester area and to generate knowledge and tools that could be evaluated for broader deployment by the NHS, for improved health and care across the system.

LEARN MORE IN OUR NEWSROOM